J.P. Morgan Ups PT On AVEO To $25

J.P. Morgan, citing its portfolio analysis along with “Biotech Week” findings, has raised its price target on AVEO Pharmaceuticals AVEO from $22 to $25 and is reiterating its Overweight rating on the stock. Says J.P. Morgan, in the report, “[The price target adjustment] is based on increasing conviction in tivozanib's probability of success in ongoing phase 3 trials in renal cell carcinoma (RCC) from several recent events including 1) a delay in the timing of phase 3 TIVO-1 data (implies that tivozanib may be performing better than expected), 2) a recent DSMB safety review (indicates no safety concerns thus far in the ongoing trial), and 3) phase 3 data for Pfizer's axitinib (didn't raise the competitive bar). Give this view, we are modestly increasing our tivozanib sales estimates and raising our YE11 price target.” AVEO closed at $19.12 yesterday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsAVEO Pharmaceuticals Inc.J.P. Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!